Drug news
FDA approves Iperia ProMRI HF-T cardiac resynchronization defibrillator for heart failure- Biotronik
The FDA has announced approval of Iperia ProMRI HF-T, a cardiac resynchronization defibrillator, from Biotronik, that provides heart failure patients with access to diagnostic magnetic resonance imaging (MRI) scans. The Iperia HF-T was developed with Biotronik's ProMRI, Home Monitoring, and CLS technology, creating an advanced cardiac resynchronization therapy defibrillator (CRT-D) which ensures patients have access to 1.5T scans without an exclusion zone. Home Monitoring provides automatic daily transmission of data relating to arrhythmic events and heart failure statistics, which have been shown to reduce all-cause mortality by more than 50 percent.